Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2015

01.09.2015 | Urologic Oncology

FDG PET–CT for Lymph Node Staging of Bladder Cancer: A Prospective Study of Patients with Extended Pelvic Lymphadenectomy

verfasst von: In Gab Jeong, MD, PhD, Sungwoo Hong, MD, Dalsan You, MD, PhD, Jun Hyuk Hong, MD, PhD, Hanjong Ahn, MD, PhD, Choung-Soo Kim, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this study was to evaluate the diagnostic accuracy of [18F] fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET–CT) for lymph node (LN) staging of bladder cancer patients undergoing radical cystectomy (RC) with extended pelvic lymphadenectomy compared to conventional CT.

Methods

A total of 61 patients underwent FDG PET–CT before RC and extended pelvic lymphadenectomy. A template for extended pelvic lymphadenectomy to the level of the inferior mesenteric artery was divided into 11 anatomic nodal packets. Definitive pathologic findings of resected LNs were correlated with the results of FDG PET–CT and CT alone in a patient- and nodal packet-based manner.

Results

Among the 61 patients, pathological staging confirmed LN metastasis in 17 patients (27.9 %). In total, 627 LN packets (2580 LNs) were resected and histologically evaluated. The mean number of LNs removed was 42 (median 40; range 22–118). Of the 627 LN packets removed, 27 packets (4.3 %) were positive for LN metastasis based on pathologic analysis. On a patient-based analysis, FDG PET–CT and conventional CT showed a sensitivity of 47.1 and 29.4 %, respectively, specificity of 93.2 and 97.7 %, respectively, positive predictive value (PPV) of 72.7 and 78.2 %, respectively, and negative predictive value (NPV) of 82.0 and 78.2 %, respectively. On a nodal packet-based analysis, sensitivity, specificity, PPV, and NPV were 14.8, 97.8, 23.5, and 96.2 %, respectively, for PET-CT and 11.1, 98.7, 27.3, and 96.1 %, respectively, for conventional CT.

Conclusions

Combined FDG PET–CT did not improve the diagnostic accuracy of conventional CT for the detection of LN metastasis in bladder cancer patients scheduled for RC.
Literatur
1.
Zurück zum Zitat American Cancer Society. Cancer facts & figures 2013. Atlanta: American Cancer Society; 2013. American Cancer Society. Cancer facts & figures 2013. Atlanta: American Cancer Society; 2013.
2.
Zurück zum Zitat Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.PubMed Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.PubMed
3.
Zurück zum Zitat Niegisch G, Lorch A, Droller MJ, Lavery HJ, Stensland KD, Albers P. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol. 2013;64:355–7.PubMedCrossRef Niegisch G, Lorch A, Droller MJ, Lavery HJ, Stensland KD, Albers P. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol. 2013;64:355–7.PubMedCrossRef
4.
Zurück zum Zitat Moses KA, Zhang J, Hricak H, Bochner BH. Bladder cancer imaging: an update. Curr Opin Urol. 2011;21:393–7.PubMedCrossRef Moses KA, Zhang J, Hricak H, Bochner BH. Bladder cancer imaging: an update. Curr Opin Urol. 2011;21:393–7.PubMedCrossRef
5.
Zurück zum Zitat Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693–6.PubMedCrossRef Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693–6.PubMedCrossRef
6.
Zurück zum Zitat Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003;180:1045–54.PubMedCrossRef Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003;180:1045–54.PubMedCrossRef
7.
Zurück zum Zitat Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785–808.PubMedCrossRef Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785–808.PubMedCrossRef
8.
Zurück zum Zitat von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–22.CrossRef von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–22.CrossRef
9.
Zurück zum Zitat Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27:4314–20.PubMedCentralPubMedCrossRef Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27:4314–20.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, Werbrouck P. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641–7.PubMedCrossRef Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, Werbrouck P. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641–7.PubMedCrossRef
11.
Zurück zum Zitat Apolo AB, Riches J, Schoder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973–8.PubMedCentralPubMedCrossRef Apolo AB, Riches J, Schoder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973–8.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106:658–63.PubMedCrossRef Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106:658–63.PubMedCrossRef
13.
Zurück zum Zitat Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32:1412–7.PubMedCrossRef Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32:1412–7.PubMedCrossRef
14.
Zurück zum Zitat Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol. 2008; 179:34–45.PubMedCrossRef Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol. 2008; 179:34–45.PubMedCrossRef
15.
Zurück zum Zitat Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 2014;114:389–9. Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 2014;114:389–9.
16.
Zurück zum Zitat Hitier-Berthault M, Ansquer C, Branchereau J, Renaudin K, Bodere F, Bouchot O, Rigaud J. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol. 2013;20:788–96.PubMedCrossRef Hitier-Berthault M, Ansquer C, Branchereau J, Renaudin K, Bodere F, Bouchot O, Rigaud J. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol. 2013;20:788–96.PubMedCrossRef
17.
Zurück zum Zitat Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, Bouchelouche K. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol. 2011;45:122–8.PubMedCrossRef Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, Bouchelouche K. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol. 2011;45:122–8.PubMedCrossRef
18.
Zurück zum Zitat Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012;53:943–9.PubMedCrossRef Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012;53:943–9.PubMedCrossRef
19.
Zurück zum Zitat Birkhauser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 2013;64:953–60.PubMedCrossRef Birkhauser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 2013;64:953–60.PubMedCrossRef
20.
Zurück zum Zitat Tilki D, Brausi M, Colombo R, et al. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013;64:266–76.PubMedCrossRef Tilki D, Brausi M, Colombo R, et al. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013;64:266–76.PubMedCrossRef
21.
Zurück zum Zitat Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–21.PubMedCrossRef Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–21.PubMedCrossRef
22.
Zurück zum Zitat Maurer T, Souvatzoglou M, Kubler H, et al. Diagnostic efficacy of [11C] choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61:1031–8.PubMedCrossRef Maurer T, Souvatzoglou M, Kubler H, et al. Diagnostic efficacy of [11C] choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61:1031–8.PubMedCrossRef
23.
Zurück zum Zitat Beggs AD, Hain SF, Curran KM, O’Doherty MJ. FDG-PET as a “metabolic biopsy” tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging. 2002;29:542–6.PubMedCrossRef Beggs AD, Hain SF, Curran KM, O’Doherty MJ. FDG-PET as a “metabolic biopsy” tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging. 2002;29:542–6.PubMedCrossRef
Metadaten
Titel
FDG PET–CT for Lymph Node Staging of Bladder Cancer: A Prospective Study of Patients with Extended Pelvic Lymphadenectomy
verfasst von
In Gab Jeong, MD, PhD
Sungwoo Hong, MD
Dalsan You, MD, PhD
Jun Hyuk Hong, MD, PhD
Hanjong Ahn, MD, PhD
Choung-Soo Kim, MD, PhD
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4369-7

Weitere Artikel der Ausgabe 9/2015

Annals of Surgical Oncology 9/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.